Cipla Limited and Boehringer Ingelheim India Pvt. Ltd. (BI) announced that they have entered into a partnership to co-market three new oral anti-diabetics drugs Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin) in India.
As per the International Diabetes Federation, India is home to 77 million adults aged between 20 and 79 years with diabetes, ranking second behind China; and is poised to reach 134.2 million patients by 2045.
The Indian diabetes market is valued at Rs 1,45,451 million and is growing at 10.35% (IMS MAT May 2020) with the oral anti-diabetic market being valued at Rs 1,07,354 million and growing at 11.34% (IMS MAT May 2020).
Empagliflozin is approved for glucose-control in patients with type-2 diabetes; it is also approved for reducing the risk of cardiovascular death, in patients with type-2 diabetes and established cardiovascular disease, the Company said in a press statement.
Commenting on the partnership, Nikhil Chopra, Executive Vice President & CEO – India Business, Cipla said, “We are committed to providing access to innovative medications that address unmet patient needs. Diabetes continues to be a focus area for Cipla and with a strategic partnership with Boehringer Ingelheim coupled with our strong brand building, patient access and reach capabilities, we will be at the forefront of providing holistic diabetes care.”
Commenting on the expanded partnership, Sharad Tyagi, Managing Director – Boehringer Ingelheim India said, “We are excited about the expansion of our partnership with Cipla to provide pioneering medicines through the new oral anti-diabetics drugs. As a dedicated organization to the field of diabetes, we aim to provide wider access and innovative solutions to the medical fraternity and patients with one of the most comprehensive Diabetes portfolios in the country.”
